Calithera Biosciences (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fourth quarter and year ended December 31, 2017.  As of December 31, 2017, cash, cash equivalents and investments totaled $186.2 million.

As quoted in the press release:

“2017 was a transformative year for Calithera as we advanced each of our internally discovered first-in-class, small molecule onco-metabolism clinical candidates into broad clinical programs and announced a partnership with Incyte.” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera.  “In 2018, we will be enrolling two randomized placebo-controlled trials of our oral glutaminase inhibitor for the treatment of patients with renal cell carcinoma and a Phase 2 trial for the treatment of patients with triple negative breast cancer.  INCB001158, an inhibitor of arginase, will be in evaluated in three broad clinical trials for the treatment of patients with solid tumors in combination with a PD-1 inhibitor, chemotherapy, and epacadostat/PD-1 inhibitor, respectively.”

Click here to read the full press release.